Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer
Study sponsor: MacroGenics
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2022-07-29Actual
Enrollment · participants62Actual
Source updated2023-12-20Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.